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treatment on cancer and healthy cells, and these effects are 
generally characterized by tumor control probability (TCP) 
and normal tissue complication probability (NTCP). 
Nowadays, many attempts to create toxicities models have 
been made, simply measuring the 3D dose distribution on 
organ at risks by equivalent uniform dose (EUD) or mean 
dose. Advances in computing and the availability of many 
Machine Learning algorithms allow to catch complex 
interactions between dose and non-dose factors. Aim of this 
study was to test an 'in house software' to elaborate 
predictive model on prostate cancer patients treated in 
exclusive setting. 
Materials and Methods: A prospective study was performed 
on prostate cancer patients, treated with volumetric Arc 
Therapy radiotherapy and Image guided radiotherapy 
technique. We delivered moderate hypofractionation with a 
simultaneous integrated boost (SIB). Clinical Target Volume 
(CTV) included: prostate (CTV1, 80 Gy) and seminal vesicles 
(CTV2, 72 Gy) in the largest part of sample. Cumulative dose-
volume histograms (DVHs) of calculated treatment plans were 
exported from the Eclipse TPS. Data were analyzed by a 
software package, written in R and internally developed, 
called MODDICOM. By specific functions created ad hoc, we 
analysed the impact of Vdose for gastrointestinal and 
genitourinary toxicity, both acute and late (using RTOG and 
CTCAE 4.0 scales). Dose from treatment planning and 
simulated delivery was evaluated to calculate the Niemierko's 
EUD-based NTCP and TCP values. To calculate the EUD-based 
NTCP, we used parameterizations of the dose-response 
characteristics using Lyman NTCP formula.  
Results:
A total of 123 patients were recruited. Using MODDICOM we 
found a significant correlation (Mann-Whitney Test p=0,054, 
Logistic Model p=0.00692, Cox Model p=0.0198) between a 
Vdose of 59,5 Gy and late rectal toxicity probability of Grade 
1, in terms of proctitis and rectal haemorrhage from CTCAE 
4.0. This result agrees with the literature, in particular with 
QUANTEC revision of constraints for Radiotherapy. Moreover, 
toxicity and rectal EUD significantly correlate (p=0.06827). A 
EUD based DVH-reduction method, was used by MODDICOM to 
compute NTCP. Our patients were distributed on or close to 
an S slope showing that 50% probability of late G1 rectal 
toxicity is present with a mean delivered uniform dose of 
66,5 Gy.  
Conclusions: MODDICOM, tested on this setting of patients, 
showed good proof of reliable, providing results according 
with the common criteria used to validate Radiation 
Treatment plans. The development of this software could 
help clinicians to elaborate predictive models, in order to 
analyze patients series for radiobiological modeling purposes.  
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Purpose/Objective: Prostate cancer (PrCa) is the most 
common cancer for men with a ten-years overall survival (OS) 
between 60 and 70%. Radiotherapy, which is one of the main 
treatment for PrCa, is limited by normal tissue toxicity. 
Therefore, a further increase in OS requires a specific 
radiosensitisation of PrCa without further damage to normal 
tissue. It was tested by us whether targeting of repair of DNA 
double-strand breaks can be implemented for a specific 
radiosensitisation.  
Materials and Methods: Previously, we reported a functional 
hierarchy between DSB repair pathways to ensure faithful 
and fast repair. Deregulation of this hierarchy switches the 
repair to an inaccurate repair mode which is PARP1-
dependent (PARP1-EJ). In the current study, we investigated 
the hypothesis that this switch is responsible for PARPi-
mediated radiosensitization in tumor cells. To that end, we 
firstly analyzed the radiosensitization effect of Olaparib on 
15 different tumor cell lines. We characterized cells which 
are radiosensitized (responders) and others which are not.  
Results: By analysing several different tumor cell lines it is 
shown by us that PrCa cell lines often shift to this DSB repair 
mode. As a consequence in this PrCa cell lines DSB repair is 
depressed when PARP1 is knocked down by the specific 
inhibitor olaparib (responders). In contrast, no reduction in 
DSB repair was seen in cells still using the classical NHEJ 
(non-responders). In responders inhibition of PARP1 by 
olaparib also results in a drastic radiosensitisation, which was 
not seen for non-responding tumor cells and likewise not for 
normal cells. It was also shown by us that this shift to PARP1-
EJ results from defect in Ku-binding, which is the initial step 
of NHEJ. Biomarkers are now tested which can be used to 
detect PrCa shifted to PARP-EJ in order to identify patients 
which might be treated by RT in combination with PARP1 
inhibition. 
Conclusions: Overall our data indicate that in PrCa where 
DSB is shifted to the PARP1 dependent EJ a specific 
radiosensitisation is achieved by the PARP1 inhibitor olaparib 
without further increase in normal tissue toxicity. 
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Purpose/Objective: We conducted a retrospective analysis of 
stage IVA uterine cervical cancer patients from several 
clinical trials of carbon ion radiotherapy (C-ion RT) in 
National Institute of Radiological Sciences. The purpose of 
this study was evaluation of the toxicity and efficacy of C-ion 
RT for FIGO stage IVA uterine cervical cancer. 
Materials and Methods: Between June 1995 and January 
2014, we have conducted 8 clinical trials of C-ion RT for 
locally advanced squamous cell carcinoma or adenocarcinoma 
of the cervix, and 29 patients with FIGO stage IVA uterine 
cervical cancer were identified in 7 clinical trials. Mean age 
was 56 years old (range 31-79 years old). Median tumor size 
was 6.7 cm (range 3.5-11 cm). Patients with rectal invasion 
were excluded from this analysis because these cases were 
ineligible in our clinical trial. Nineteen of 29 patients had 
enlarged lymph nodes in pelvis. Histologically, 20 patients 
had squamous cell carcinoma and 9 had adenocarcinoma. C-
ion RT was performed as a dose-escalation study at the 
beginning, total dose to cervical tumor was 52.8-74.4 gray 
equivalents, and concurrent chemotherapy was combined in 
4 patients. 
Results: The median follow up time was 28.1 months (range 
4.2-213.8 months). The numbers of Grade 2 or higher major 
late complications were 2 patients (6.9%) in the bladder, and 
6 patients (20.7%) in the rectosigmoid colon. Vesicovaginal 
fistula was observed in 6 patients after the treatment. The 3 
years overall survival rates (3yOS) was 46.7%, the 3 years 
local control rates (3yLC) was 64.9%, and the 3 years 
progression free survival rates (3yPFS) was 33.6%. The 3yOS, 
3yOS, and 3yPFS of patients with squamous cell carcinoma 
were 44.9%, 62.2%, and 34.9%, respectively. Those with 
adenocarcinoma were 52.5%, 75.0%, and 23.9%, respectively. 
Conclusions: Although the number of patients in this analysis 
was small, these result suggested that C-ion RT for FIGO 
stage IVA uterine cervical cancer would be an effective 
method.  
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Purpose/Objective: To determine the recommended 
preoperative dose of large-field IMRT chemoradiation along 
with simultaneous integrated boost (SIB) dose escalation on 
the tumor and pelvic nodes in locally advanced cervical 
carcinoma (LACC). 
Materials and Methods: A radiation dose of 40 Gy over four 
weeks, 2 Gy per fraction, was delivered to the tumor and the 
lymphatic drainage (planning target volume, PTV3), which 
encompassed a volume larger than standard (upper field 
border: L3 vertebra), concurrently with chemotherapy 
(cisplatin and 5-fluorouracil). Radiation dose was escalated 
to the pelvic nodes (PTV2) and macroscopic disease (PTV1) 
with a SIB strategy. Three dose levels were planned as shown 
in Table 1 up to a dose of 50/2.5 Gy on PTV1. Patients were 
treated in cohorts of three to six per group using a phase I 
study design. The recommended dose was exceeded if 2 of 6 
patients in a cohort experienced dose-limiting toxicity (DLT). 
 
Results: 19 patients (median age: 46 years; FIGO stage IB2: 
3, IIB: 10, IIIA: 4, IIIB: 2) were enrolled. Median follow-up was 
36 months (9–60 months). The predominant DLTs were 
gastrointestinal . Since two DLTs (grade 3 diarrhoea, n=2), 
were observed in 6 patients at level III, the decision was to 
close the trial and to consider level II as the recommended 
phase II dose. In the post-operative period, 2 (10.5%) patients 
showed grade 3 GU complications. Concerning long term 
toxicity, actuarial 2y GU toxicity (≥ grade 2) free survival was 
83.6%, neither severe GI complications (≥2) nor late skin 
toxicity (≥2) were observed. Planning constraints for normal 
tissues were always respected except in the case of small 
bowel where only 2 patients respected V15<120 cc 
constraint; in the majority of LACC it was largely exceeded 
with a median value of 268.9 cc (range 96-481 cc). Three of 
the four patients with severe GI toxicity did not meet the 
QUANTEC small bowel constraint V15<120 cc. Concerning 
pathologic response 12 (63.1%) complete response or 
microscopic residual disease were recorded. The 2-year local 
control was 89.5% (median LC: not reached), while the 2-year 
disease free survival (DFS) was 82.0% (median DFS: not 
reached). Death of disease was recorded in 2 of 18 patients 
(10.5%) and the 2-year overall survival (OS) was 88.8% 
(median OS: not reached).  
Conclusions: In a series of 19 LACC patients treated by SIB-
IMRT chemoradiation followed by radical surgery, 40 Gy on 
lumboaortic nodes and 45 Gy on pelvic nodes and 
macroscopic disease were the recommended doses. 
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